SCHEMBL22764883

SCHEMBL22764883

COc1ccc(S(=O)(=O)Nc2cccc3ccc(CN(C)C)nc23)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 7/20 0.47
GLO1 Q04760 5/20 0.47
EIF2AK3 Q9NZJ5 1/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
MEN1 O00255 2/20 0.45
AGTR1 P30556 2/20 0.43
PAX8 Q06710 1/20 0.43
MITF O75030 1/20 0.42
S1PR4 O95977 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
S1PR1 P21453 1/20 0.42
OPRK1 P41145 1/20 0.42
HTT P42858 1/20 0.42
CKS1B P61024 1/20 0.42
SKP2 Q13309 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PDE10A Q9Y233 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30471539 1.00 SLC40A1 (0.47) SLC40A1GLO1EIF2AK3KMT2ATDP1
SCHEMBL26053737 0.86 KMT2A (0.56) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL30471546 0.85 SLC40A1 (0.53) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22765014 0.85 SLC40A1 (0.53) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22764941 0.85 SLC40A1 (0.63) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22765091 0.82 TDP1 (0.54) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22764939 0.82 KMT2A (0.67) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22578601 0.81 SLC40A1 (0.64) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL22764927 0.81 SLC40A1 (0.64) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL30471632 0.81 SLC40A1 (0.64) SLC40A1GLO1KMT2ATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents OTAGO INNOVATION LIMITED (NZ) 2023-07-04 US disclosed
US-20200385354-A1 Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents OTAGO INNOVATION LIMITED (NZ) 2020-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents NQO2, SDHA, SIRT5 SLC40A1 4081/4885GLO1 369/4885EIF2AK3 1807/4885
US-20200385354-A1 Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents NQO2, SDHA, SIRT5 SLC40A1 4081/4885GLO1 369/4885EIF2AK3 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.